Bio-Rad Laboratories, Inc. Class A Common Stock vs Equinix Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Equinix Inc trades at $1,024.21 (market cap $100.95B). The key difference: Equinix Inc is far larger — about 12.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Equinix Inc pays a 1.92% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | EQIX | |
|---|---|---|
Market Cap | $8.04B | $100.95B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $1.12K |
52-Week Low | $241.71 | $726.09 |
Enterprise Value | $7.85B | $121.23B |
Dividend Yield | — | 1.92% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
EQIX trades at $1,039.53, down 1.11% on the day, with a bullish technical signal and strong analyst support (74.51% buy ratings). Revenue grew to $9.22B in 2025, with net income reaching $1.35B, though recent quarters showed mixed earnings results. The company benefits from AI infrastructure demand, evidenced by partnerships with Cisco and NVIDIA (Business Wire, 2026-06-17).
Outlook remains positive due to recurring revenue growth and AI tailwinds, but high valuation (P/E 71.89) and negative cash flow (-$1.26B in 2025) pose risks. Debt levels are rising, with debt-to-asset ratio at 47.13% in 2025. The consensus price target of $1,110 suggests upside potential if execution aligns with AI-driven demand.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →